This investigation focused on obtaining a further understanding of the role of heme oxygenase-1 (HO-1) in tolerance induction. Hearts from C57BL/6 (H-2 b ) mice survived long-term when transplanted into BALB/c (H-2 d ) recipients treated with the tolerance-inducing regimen of anti-CD40L antibody (MR-1) plus donor-specific transfusion (DST). Grafts did not, however, survive long-term in (HO-1 −/− ) recipients given the same treatment. Similarly, long-term survival induced by DST was ablated when HO-1 activity was blocked by zinc protoporphyrin IX (ZnPPIX). We further asked whether modulation of HO-1 expression/activity could be used to promote the induction of graft tolerance. DST alone (day 0) failed to promote any prolongation of survival of DBA/2 (H-2 d ) hearts transplanted into B6AF1 (H-2 b,k/d ) recipients. However, longterm survival and (dominant peripheral) tolerance were readily induced when DST was combined with induction of HO-1 expression by cobalt protoporphyrin IX (CoPPIX). HO-1 induction plus DST led to a significant up-regulation of Foxp3, TGF-β, IL-10, and CTLA4, which suggests a prominent role for CD4+CD25+ regulatory T cells (Tregs). In fact, the tolerogenic effect of HO-1 plus DST was dependent on CD4+CD25+ Tregs as suggested by adoptively transferring these cells into irradiated recipients under various regimens. Taken together, these findings show that expression of HO-1 in a graft recipient can be essential for long-term graft survival and for induction of tolerance and that modulation of HO-1 expression/activity can be used therapeutically to synergize in the generation of graft tolerance.
nduction of antigen specific tolerance remains the ultimate goal in clinical organ and cell transplantation as it would eliminate the need for continuous immunosuppression [reviewed in (1) ]. One strategy leading to tolerance induction against a transplanted organ consists of infusing blood from the organ donor, an approach known as donor-specific transfusion (DST) (2) . Although the mechanisms underlying tolerance induction by DST are not fully understood, clonal deletion of alloreactive T cells (3) and generation of immunoregulatory CD25+CD4+ T cells are important in the process (4) .
A growing body of evidence suggests that expression of the stress-responsive gene heme oxygenase-1 (HO-1) can promote the survival of transplanted organs [reviewed in (5, 6) ]. HO-1 is a rate-limiting enzyme in the catabolism of heme into biliverdin via a process that releases free Fe and carbon monoxide (CO) (7) . Others and we have shown that expression of HO-1 in a transplanted organ can promote the survival of that transplant (8, 9) , i.e., the organ can contribute to its own survival (10) (11) (12) . Presumably, the protective effect of HO-1 relies on the antiapoptotic (13, 14) , anti-inflammatory (15) , and anti-proliferative effects (16) of the products that are generated via the catabolism of heme [reviewed in (17) ].
In the recipient, HO-1 modulates the T cell activation and proliferation that normally leads to rejection (18) (19) (20) . We have recently proposed that HO-1 promotes the deletion of activated T cells by the process referred to as activation induced cell death (AICD) (21) . As AICD is an important mechanism via which tolerance can be induced (22) , we asked whether expression of HO-1 in the graft recipient was involved in the induction of tolerance.
The combination of blockade of the T cell co-stimulatory CD40/CD40L signal transduction pathway and DST is efficient in inducing tolerance against transplanted organs (23) . The tolerogenic effect of DST plus CD40/CD40L blockade has been associated with the expression of HO-1 in the graft (24) , which inhibits the development of chronic graft rejection (25, 26) . Whether expression of HO-1 in the graft recipient can regulate long-term graft survival and tolerance induction remained to be established and was the main focus of this study. We tested the hypothesis that expression of HO-1 might be involved in tolerance induction by DST plus CD40/CD40L blockade or tolerance induction by DST alone. We found that HO-1 expression and activity are obligatory for tolerance induction in these systems. In addition, we show that induction of HO-1 expression by protoporphyrins can synergize with DST to achieve donorspecific tolerance involving regulatory T cells.
MATERIALS AND METHODS

Animals
, and male/female FVB (H-2 q ) mice were purchased from Jackson Lab. Inc. (Bar Harbor, ME). F1 mice between DBA/2 and FVB were bred in our animal facility. Wild-type BALB/c (H-2 d ) and BALB/c-Hmox1 tm1Mlee (27) were a kind gift from Drs. Yet and Perrella (Brigham and Women's Hospital, Boston, MA). Mice were maintained in a specific-pathogen free facility, used for experiments at age 6-10 weeks, and treated according to the guidelines of the animal use committee of the Beth Israel Deaconess Medical Center. 
Cells and culture medium
Murine leukocytes (spleen and lymph nodes) were purified, including the isolation of CD4+/CD25+ cells with T cell enrichment columns (R&D Systems, Minneapolis, MN) or by a MACS Pan T cell isolation kit (Miltenyi Biotec Inc., Auburn, CA), CD3 + T cells were more than 85-95% pure. Cells were maintained in supplemented RPMI 1640 culture media (Bio Whittaker Inc., Walkersville, MD).
Reagents
Cobalt-and zinc-protoporphyrin (CoPPIX and ZnPPIX; Frontier Scientific Inc., Logan, UT) were dissolved in 0.2 N NaOH, neutralized with 1N HCl, sterilized, and stored at -80°C. Exposure to light was avoided. Monoclonal antibodies against mouse CD3 (17A2, and 145-2C11), CD4 (H129.19), CD8a (53-6.7), and CD25 (7D4) were obtained from BD PharMingen Inc. (San Diego, CA). Anti CD40-ligand antibody (MR-1) was purchased from Taconic Inc. (Boston, MA).
Cardiac transplantation and histology
Heterotopic heart transplantation, second grafting, and histology was performed as described previously (28) . Beating of the graft was monitored by daily palpation and the "contraction strength" was scored from 1 to 4. Graft rejection was defined as cessation of beating and was confirmed by direct inspection and subsequent histological examination.
Treatment protocol
Donor and recipient mice were treated either with CoPPIX or ZnPPIX at 5 mg/kg/day i.p., donor treatment starting from 2 days before graft harvest (day -2 and day -1), recipient treatment for 15 days starting from one day before DST or transplant without any further treatment. Donor strain spleen cells (20×10 6 i.v.) were used for DST on day -7 or day 0. Anti-CD40L antibody (MR-1) was given i.p. on days -7, -5, and -3 at a dose of 250 μg.
Protein extraction and Western blot
DBA/2 mice were injected i.p. with CoPPIX at a dose of 5 mg/kg. Non-treated DBA/2 mice served as naïve controls. Animals were killed 2, 4, and 7 days following treatment. The heart and spleen were excised, and samples were snap-frozen in liquid nitrogen. Protein extracts were prepared, electrophoresed under denaturing conditions (10% polyacrylamide gels), and transferred on polyvinyldifluoridine membranes (Millipore, Bedford, MA) essentially as described before (15) . HO-1 was detected using the rabbit anti-human HO-1 polyclonal antibody (StressGen, Victoria, CA); β-actin was detected using the goat anti-mouse β-actin antibody (1A4, Sigma-Aldrich Corporation). Primary antibodies were detected using horseradish peroxidase conjugated donkey anti-rabbit or goat anti-mouse IgG secondary antibodies (Pierce, Rockford, IL). Proteins were visualized using Enhanced Chemi Luminescence (Amersham Life Science Inc., Arlington Heights, IL) according to the manufacturer's instructions; these were stored in the form of photo-radiographs (BiomaxTMMS; Eastman Kodak, Rochester, NY). The level of HO-1 expression was normalized with α-actin expression and quantified using ImageQuant software (Molecular Dynamics, Sunny Vale, CA).
HO activity assay
DBA/2 mice were either given no treatment or treated with CoPPIX or ZnPPIX at a dose of 5 mg/kg, i.p. (n=10 per group). One day after treatment, the animals were killed, the spleen and the graft were excised, and the tissue samples were frozen at -80°C. HO-1 activity was evaluated essentially as described before (29) .
Adoptive transfer experiment
Spleen plus peripheral lymph node cells (50×10 6 ) from naïve or tolerant animals were injected via the penile vein of sub-lethally irradiated (6.5 Gy, 137 Cs) B6AF1 recipients immediately after grafting DBA/2 hearts. The grafts were excised upon rejection or after 100 days for histology.
Mixed lymphocyte cultures
As described previously (21) . In brief, responder leukocytes (5×10 5 /well) from spleens of recipients taken 5 days following transplantation were co-cultured for 3 days with irradiated (25Gy, 137 Cs) naïve DBA/2 splenocytes (5×10 5 /well) in 96-well round-bottom plates. 3 Hthymidine incorporation was used to measure proliferation (triplicates, repeated 3 times).
Flow cytometric analysis
Cells were stained with fluorochrome conjugated isotype control Abs, or specific anti-CD4 and/or anti-CD25 antibodies (BD PharMingen). + cells enumerated.
Real-time PCR
As recently described (21) . Total RNA was extracted from lymph nodes taken 1 or 2 weeks after transplantation (RNeasy kit; Qiagen Inc., Valencia, CA). Total RNA (1μg) was transcribed to cDNA (murine leukemia virus transcriptase, Applied Biosystems, Foster City, CA) in a final volume of 100 μl containing 1× RT buffer, 5.5 mM MgCl 2 , 0.5 mM dNTP, 0.4 U/μl RNase inhibitor, 2.5 μM random hexamers, and 3.125 U/μl reverse transcriptase. Samples were held at 25°C for 10 min, incubated at 48°C for 30 min, heated at 95°C for 5 min, and stored at -20°C. Real-time PCR was performed by using the ABI PRISM ® 7700 Sequence Detection System. All materials were purchased from Applied Biosystems. cDNA samples were analyzed in duplicates. GAPDH was used to standardize the amount of sample cDNA added to the reaction. Relative quantification of all target genes was analyzed based upon a comparative C T method as suggested by Applied Biosystems. All results are relative expression levels to the examined genes of purified CD4 + CD25
-T cells. Foxp3 and CTLA4 mRNA expression levels in each sample are adjusted with those of CD3 mRNA expression levels in order to normalize to a per T cell basis.
Statistics
Kaplan-Meier analysis was used for graft survival; log-rank test to compare statistical significance. All other data are expressed as mean ± SEM. Statistical analysis among groups was performed by one-way ANOVA, and Fisher's PSLD was used for a post-hoc test. A P value of <0.05 was considered statistically significant.
RESULTS
HO-1 expression is required to sustain long-term graft survival afforded by DST plus CD40/CD40L blockade
The combination of DST, given 7 days before transplantation, and anti-CD40L antibody (MR-1) resulted in 100% long-term survival of hearts transplanted from C57BL/6 into Balb/c mice (Fig. 1A) as well as from Balb/c into C57BL/6 mice (Fig. 1B) . Hearts from HO-1 deficient (HO-1 −/− ) BALB/c mice also survived long-term (>100 days) when transplanted into DST plus MR-1 treated C57BL/6 recipients ( Fig. 1A) . However, DST plus MR-1 failed to promote long-term graft survival when hearts from C57BL/6 mice were transplanted into HO-1 deficient (HO-1 −/− ) BALB/c recipients, i.e., all grafts were rejected within 24 days after transplantation (n=3, MST=16.0±4.2 days, P<0.02 vs. HO-1 +/+ recipients; Fig. 1 ). These data show that expression of HO-1 in the recipient is obligatory to sustain long-term graft survival and tolerance induction afforded by DST plus CD40/CD40L blockade.
HO activity is required for and synergizes with DST to promote tolerance
Having established that HO-1 expression in the recipient is required to sustain graft survival when the recipient is treated with DST + MR-1, we asked whether HO enzymatic activity was essential for tolerance induction by DST. Administration of CoPPIX up-regulated HO-1 protein expression significantly in the heart and spleen of adult mice, as compared with untreated mice (Fig. 2) . Maximal expression was detected one day after CoPPIX injection ( Fig. 2A, B) . HO-1 enzymatic activity was also significantly enhanced by CoPPIX administration (Fig. 2C) , while this was not the case for ZnPPIX. Without further treatment, DST given at day -7 before transplantation led to 50% (4/8) of DBA/2 (H-2 d ) heart grafts surviving for more than 100 days in B6AF1 recipients (P<0.005 vs. untreated control; Fig. 3A ). Inhibition of HO activity by ZnPPIX administration to the recipient from day -8 (one day before DST) to day 6 after transplantation abrogated the tolerogenic effect of DST (day -7) with none (0/9) of the grafts surviving long-term (MST: 13 days; P<0.002 vs. DST alone; Fig. 3A ).
In contrast, induction of HO-1 expression and activity by CoPPIX administration plus DST (day -7) led to 100% (7/7) of the grafts surviving for more than 100 days (P<0.001 vs. DST alone, Fig. 3A ). These data indicate that DST (day -7) plus induced HO-1 are at least additive in their effects. DST + CoPPIX treated recipients of long-term surviving grafts (100 days) were antigenspecifically tolerant. B6AF1 (H-2 b,k/d ) recipients carrying a long-term surviving (100 days) DBA/2 heart were challenged with a second heart. While these mice accepted a second DBA/2 (H-2 d ) heart for more than 100 days without further treatment, third party FVB (H-2 q ) hearts where promptly rejected within 11 days (MST=10.3±0.9, n=3 for each group, P<0.001 vs. DBA/2 2nd grafts, Fig. 3B) , with a tempo of rejection that was not significantly different from that of FVB hearts in naïve B6AF1 recipients (n=3, MST=10±0.0 P=ns vs. 3rd party allografts). Histological examination of the transplanted hearts revealed that the morphological architecture of second DBA/2 grafts (inspected at over 100 days after transplantation) was well preserved, while that of rejected FVB third party grafts upon harvest after rejection showed severe tissue destruction and cellular infiltration (Fig. 3C ).
Given that DST on day -7 alone would not be applicable to most clinical situations, we asked whether induction of HO-1 expression and activity could be used to promote the tolerogenic effect of DST used at the time of transplantation, which would be applicable to organs retrieved from deceased donors. When DST was given to B6AF1 recipient mice immediately after transplantation with DBA/2 hearts (day 0), these grafts were promptly rejected (n=6, MST=10.3±0.8, Fig. 3D ). Rejection occurred with a similar tempo to those transplanted into untreated controls (n=6, MST=11.2±0.5, P=ns vs. DST alone, Fig. 3D ). Induction of HO-1 expression by CoPPIX administration to the recipient from day -1 to day +13 post-transplant together with DST (day 0) prolonged graft survival significantly (P<0.001 vs. DST alone) with 7 of 8 (87.5%) grafts surviving long-term (>100 days, Fig. 3D ). Conversely, blocking HO-1 activity with ZnPPIX had no significant graft prolongation effect in recipients treated with DST on day 0 (n=6, MST=9.1±0.9, P=ns vs. control and DST alone, Fig. 2D ). CoPPIX treatment of the recipient without DST resulted in a significant prolongation of allograft survival, with 2 of 6 grafts surviving long term (i.e., >100 days) and a MST of the remaining 4 grafts of 21.0±5.1 days, which was still significantly greater than in untreated (n=6, MST 11.1±0.5 days, P<0.005, Fig. 3E ) or ZnPPIX treated (n=6, MST=11.3±1.1, P<0.01) recipients. The combined effect of DST (day 0) plus HO-1 in terms of achieving long-term survival (tolerance) was significantly greater than HO-1 induction alone (P<0.03). As with DST (day -7) + CoPPIX treatment, those recipients given DST on day 0 + CoPPIX in which allografts survived long-term were antigenspecifically tolerant as tested with second grafts of DBA/2 (n=3) and of third-party (FVB, n=3) donors (data not shown).
HO-1 promotes donor-specific "peripheral dominant tolerance" to cardiac allografts
To assess whether up-regulation of HO-1 plus DST induced "peripheral dominant tolerance" to the long-term surviving DBA/2 (H-2 d ) cardiac allografts, B6AF1 (H-2 b,k/d ) recipients carrying a long-term surviving DBA/2 transplanted heart were challenged with a second transplanted heart from DBA/2 × FVB F1 (n=5) mice (H-2 d/q ). All DBA/2 × FVB F1 grafts were accepted for more than 100 days (Fig. 4) antigens to which tolerance was established and H-2 q , the third-party antigens, are presented by the same antigen-presenting cells. By definition this phenomenon is referred to as "peripheral dominant tolerance" (31) , suggesting that induction of HO-1 expression in combination with DST promotes the induction of "peripheral dominant tolerance" to transplanted hearts.
Induction of HO-1 expression plus DST promotes generation of CD4+CD25+ regulatory T cells
To further elucidate the cellular mechanism underlying tolerance induction by HO-1 plus DST, we examined the changes of peripheral CD4+ T cell numbers and the percentage of CD25+ cells among these cells. The total number of CD4+ T cells in the lymph nodes (cervical, axillary and inguinal) was evaluated on day 14 post-transplantation of DBA/2 hearts into B6AF1 mice treated with DST on day -7 plus with either protoporphyrins or phosphate buffered saline (PBS) as a control. Induction of HO-1 expression by CoPPIX led to a significant decrease in the number of CD4+ T cells (P<0.01 vs. PBS or ZnPPIX treated controls, Fig. 5A ). However, amongst the remaining CD4+ T cells, a significant increase in the percentage of CD4+CD25+ T cells in the CoPPIX treated recipients was found when compared with PBS or ZnPPIX treated controls (P<0.05, Fig. 5B ). The increased percentage of CD4+CD25+ cells was paralleled by a significant increase in the expression of Foxp3 (Fig. 6A) , a transcription factor associated with the regulatory function of CD4+CD25+ T cells (31) , as well as increases in TGF-β, IL-10 and CTLA4 (Fig. 6B−D) .
Tolerance induction by HO-1 plus DST requires CD4 + CD25 + T cells
We probed whether the CD4+CD25+ T cells detected in recipients rendered tolerant against their grafts were functionally associated with the tolerogenic effect of HO-1 plus DST. When transplanted into sub-lethally irradiated B6AF1 recipients, hearts from DBA/2 donors survived over 100 days (data not shown). However, when transplanted into sub-lethally irradiated B6AF1 recipients that received leukocytes from naïve B6AF1 mice, DBA/2 hearts were rejected in a prompt manner (n=6, MST=12.3±1.0, Fig. 7A ). Graft rejection occurred with a similar tempo to that of DBA/2 hearts transplanted into naïve B6AF1 recipients (Fig. 3E) . However, when transplanted into sub-lethally irradiated B6AF1 recipients that received leukocytes from B6AF1 mice (treated with DST on day -7 or day 0 + CoPPIX) carrying a first DBA/2 allograft for >100 days, DBA/2 hearts were no longer rejected (>100 days survival) (Fig. 7A) . We refer to the leukocytes from the tolerant B6AF1 mice as "tolerizing leukocytes." We then examined whether CD4+CD25+ T cells within the tolerizing leukocytes were responsible for prolongation of graft survival. CD4+CD25+ T cells were depleted from the tolerizing leukocytes and the remaining cells were adoptively transferred into sub-lethally irradiated B6AF1 recipients: depletion of the CD4+CD25+ T cells abolished the graft survival prolonging effect of the transferred cells. The remaining transferred cells promptly rejected the DBA/2 hearts (n=4, MST=11.25±0.6, Fig. 7B ). These data suggest that CD4+CD25+ regulatory T cells are crucial in the establishment of donorspecific tolerance by HO-1 induction plus DST.
DISCUSSION
Our original demonstration that expression of HO-1 in a transplanted organ (8) could inhibit the rejection of that organ led to the more general concept that expression of a "protective gene," i.e., HO-1, in a graft can promote its survival [reviewed in (5)]. Most of the studies addressing this protective effect have done so in the context of ischemia/reperfusion injury [reviewed in (5, 6)]. A series of additional studies, however, have shown that HO-1 expression in a graft suppresses the development of chronic graft dysfunction (24) . This has been recently supported by two independent clinical studies suggesting that kidneys from donors with a weaker response in terms of up-regulating HO-1 to a given stress stimulus (based on a guanine-thymidine length polymorphism in the 5′ regulatory region of the human HO-1 gene) are more likely to undergo chronic dysfunction after transplantation (32, 33) . Together with the data obtained in experimental transplant models in rodents, these clinical studies strongly support the concept that grafts can express "protective genes" such as HO-1 that have a major impact on preventing graft rejection.
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Accumulating evidence suggests that expression of HO-1 may also act in a graft recipient to promote the survival of transplanted organs [reviewed in (5) ]. This was originally suggested by the observation that HO-1 overexpression in rodents by means of recombinant adenoviruses (34) or transgenic manipulation (35) could prolong the survival of cardiac transplants. Overexpression of HO-1 in these studies interfered with the activation and proliferation of alloreactive T cells that mediate graft rejection (34, 35) . In keeping with this notion, HO-1-deficient mice (HO-1 −/− ) have higher numbers of circulating activated peripheral CD4 T cells as compared with wild type (HO-1 +/+ ) mice (36, 37) , suggesting again that HO-1 controls T cell activation and proliferation.
In the context of organ transplantation, the immunoregulatory effect of HO-1 exerted on T cells is dependent on the presence of antigen presenting cells (34) , a finding in keeping with the observation that HO-1 can modulate dendritic cell maturation and inhibit alloreactive T cell proliferation (38) . Other properties of HO-1 could potentially explain its salutary effects as well. Activation of T cells was recently found to be associated with up-regulation of HO-1 expression (18) and overexpression of HO-1 in T cells was shown to inhibit their proliferation (18, 28, 39) . Presumably this effect is, at least in part, mediated by biliverdin (28) , an end product of the degradation of heme by heme oxygenase-1 (7). Taken together these observations suggest that HO-1 may act in a negative feed back loop to limit CD4 T cell activation and proliferation.
We have recently shown that biliverdin treatment can induce T cell tolerance to transplanted hearts in mice (28) and that HO-1 can trigger alloreactive T cells to undergo activation induced cell death (AICD) (21) . AICD is a regulatory mechanism that controls the extent of CD4 T cell responses and appears to be involved in some mechanisms by which tolerance can be induced (22, 40, 41) . These observations led us to test the hypothesis that HO-1 might be critical for the induction of tolerance to transplanted organs and that modulation of its expression may be used therapeutically to achieve this goal.
The combination of blockade of the CD40/CD40L co-stimulatory signal transduction pathway plus DST is potent in inducing tolerance to transplanted organs (23) . This effect has been associated with the expression of HO-1 in transplanted hearts in mice rendered tolerant by this treatment (24) . Our present data demonstrate that the tolerogenic effect of DST plus CD40/CD40L blockade requires the expression of HO-1 in the graft recipient (Fig. 1B) . In contrast, expression of HO-1 in the graft itself does not seem to be needed for tolerance induction (Fig. 1A) . These findings unequivocally implicate HO-1 expression in a graft recipient in at least some tolerance-inducing protocols. Supporting this conclusion are our observations that DST (day -7) led to 50% of the grafts showing long-term (>100 day) survival, yet, when HO activity is blocked by ZnPPIX, there were no grafts that survived long-term, a highly significant difference.
Induction of HO-1 promotes antigen specific dominant tolerance as suggested by the observation that B6AF1 (H-2 "second" antigens are presented by the same antigen presenting cell, such as occurs on cells from DBA/2 × FVB F1 mice.
One of the mechanisms underlying antigen specific dominant tolerance appears to involve CD4+CD25+ regulatory T cells (30, 42) . In keeping with this, induction of HO-1 expression plus DST increased the percentage of peripheral CD4+CD25+ T cells among CD4+ T cells in B6AF1 recipients carrying a DBA/2 cardiac transplant (Fig. 5) . Emergence of a regulatory function associated with the appearance of these CD4+CD25+ T cells is supported by the increased expression of the forkhead/winged helix transcription factor, Foxp3, a transcription factor functionally involved in the immunoregulatory effect of CD4+CD25+ T cells (31) . That these CD4+CD25+ T cells play a role in the establishment of donor-specific tolerance of DBA/2 (H-2 d ) hearts transplanted into B6AF1 (H-2 k/d,b ) recipients treated with DST plus HO-1 induction is suggested by the following observations. "Tolerizing leukocytes" from B6AF1 mice that had accepted a DBA/2 allograft long-term (after DST + HO-1 induction) failed to induce rejection of a DBA/2 heart when adoptively transferred into non-lethally irradiated B6AF1 recipients (Fig.  7A) . However, B6AF1 recipients did reject DBA/2 (H-2 d ) hearts when CD25+CD4+ T cells were depleted from the tolerizing leukocytes, and the remaining cells were adoptively transferred into non-lethally irradiated B6AF1 recipients (Fig. 7B ). These observations suggest that the ability of DST plus HO-1 to induce antigen specific peripheral dominant tolerance is sustained functionally by regulatory CD25+CD4+ T cells.
Induction of HO-1 expression appears to have beneficial effects in terms of promoting the tolerogenic effect of DST given at the time of transplantation, an effect that could be used therapeutically in clinical transplantation. While we have shown this for DST, it is possible that a similar synergistic, or an additive, effect of HO-1 induction would be observed for other approaches that are only partially effective for inducing tolerance. As a possible explanation for these findings, others and we have shown that expression of HO-1 is essential for the action of several immunomodulatory molecules including IL-10 and rapamycin to exert their therapeutic effects [reviewed in (43) ].
Our results show that HO-1 activity is essential for tolerance induction both by DST alone as well as for tolerance induction by DST + MR-1, placing HO-1 into a central role in this area. In addition, induced expression of HO-1 synergizes with DST to prolong allograft survival and achieve antigen specific tolerance. The data suggest that at least a part of the effect of inducing HO-1 expression is dependent on the presence of CD4+CD25+ regulatory T cells. We hypothesize that this key role for HO-1 relates to the generation of Treg, perhaps via the need for HO-1 expression in dendritic cells that stimulate Treg. Given these results, treatment to induce HO-1 expression should perhaps become an important component of a feasible strategy to achieve tolerance in allogeneic transplantation.
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This work was supported in part by the National Institutes of Health Grants, HL58688 (FHB) and HL67040 (MPS) and the Julie Henry Fund at BIDMC. This is publication #817 from our laboratories. Kaplan-Meier analysis of DBA/2 cardiac allograft survival in B6AF1 mice. A) Animals were either given no treatment, DST (day -7), or DST with either ZnPPIX or CoPPIX. B) Induction of HO-1 expression plus DST induces donor-specific tolerance to cardiac allografts. Long-term DBA/2 allograft accepting B6AF1 recipients (achieved by HO-1 induction plus DST on day -7 -shown in (A) allowed permanent survival of second heart grafts from DBA/2 (donor strain) mice but not from FVB (third party) mice. C) Microscopic appearance of the second heart allografts. DBA/2 and FVB grafts were examined on day 100 after transplantation or at the time of rejection if earlier than 100 days. Hematoxylin and eosin (H&E) staining (magnification, ×20); n = 3 per each group. D) Animals were given no treatment or given DST (day 0), or DST plus either CoPPIX or ZnPPIX. E) Heart recipients received no treatment or received CoPPIX or ZnPPIX. + T cells in the peripheral lymph nodes. Naïve B6AF1 mice received DST on day -7 and a DBA/2 heart on day 0. Transplant recipients were given no treatment (white bars) or were given CoPPIX (black bars) or ZnPPIX (gray bars). The total numbers of CD4 + T cells in the peripheral lymph nodes were enumerated on day 7 and day 14 post-transplantation. Values are expressed as mean ± SEM of four independent experiments; * P < 0.01 for CoPPIX+DST versus control and versus ZnPPIX+DST. B) Naïve B6AF1 mice received DST on day -7 and a DBA/2 heart on day 0. Transplant recipients were given no treatment (white bars) or were given CoPPIX (black bars) or ZnPPIX + T cells. Kaplan-Meier analysis of naïve DBA/2 cardiac allograft survival in sub-lethally irradiated B6AF1 mice. Leukocytes (50 million) obtained either from naïve or CoPPIX and DST (day -7) treated tolerant animals were adoptively transferred to B6AF1 recipients immediately after transplantation (n=4-6 per each group). The transplant recipients did not receive any further treatment. A) Sub-lethally irradiated B6AF1 mice receiving leukocytes from naïve B6AF1 mice could reject the allograft in a prompt manner, whereas DBA/2 allografts survived for more than 100 days in B6AF1 mice receiving leukocytes from tolerant B6AF1 animals (P<0.001). B) Depletion of CD4 + CD25 + T cells from the tolerizing cells abolished the graft survival prolonging effect of adoptive transfer of these cells; DBA/2 hearts were promptly rejected (P<0.005 versus tolerant cells).
